News

31.01.2020
Two Original Orphan Medicinal Products by GENERIUM  Approved for Clinical Studies фото

Two Original Orphan Medicinal Products by GENERIUM Approved for Clinical Studies

Moscow, Russia, 31 January 2020, GENERIUM, a Russian biopharmaceutical company involved in the development and commercialisation of pharmaceutical products for the treatment of orphan, oncological and socially significant diseases, received an authorization from the Russian healthcare authorities for clinical studies of two original medicinal products used in the treatment of hereditary angioedema and mucopolysaccharidosis type II (Hunter syndrome).
09.12.2019
IONTAS Antibody approved for first in patient use in the treatment of B cell Acute Lymphoblastic Leukemia фото

IONTAS Antibody approved for first in patient use in the treatment of B cell Acute Lymphoblastic Leukemia

Cambridge, UK and Moscow, Russia, 09 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that IBC Generium, leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL).
10.04.2019
 Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform фото

Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform

GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product is a biosimilar monoclonal antibody, eculizumab, indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Generium is the first company in the world to develop and market a biosimilar of eculizumab.

28.03.2019
Press-release фото

Press-release

The Russian biotechnological company “Generium”, “Oxford Immunotec” and “PharmLine” agreed on the local production of the laboratory IGRA-test (Interferon gamma release assay) T-SPOT®.TB that is used for detection of tuberculosis (TB) infection. This agreement signifies a long-term cooperation in the field of high-precision diagnostic test systems for socially significant infectious diseases.
25.02.2019
DGAP-News: CO.DON AG and GENERIUM JSC sign term sheet to out-license co.don chondrosphere(R) to Russia фото

DGAP-News: CO.DON AG and GENERIUM JSC sign term sheet to out-license co.don chondrosphere(R) to Russia

CO.DON AG and GENERIUM JSC sign term sheet to out-license co.don chondrosphere(R) to Russia.